This move marks M3’s foray into case-based problem-solving community platform and medical test preparation business in India
M3, Japan announced acquisition of a majority stake of Bengaluru-based Neuroglia Health, a provider of mobile and web-based applications for doctors and medical students in India, for an undisclosed amount.
The move marks M3’s foray into case-based problem-solving community platform and medical test preparation business in India, in addition to its existing business Health Impetus (HI). HI (under brand name of M3 India) currently runs online portals that help Indian doctors stay abreast with the latest in-research, medical news, evidence-based medicine, practice guidelines and expert articles etc.
“With this majority acquisition, M3 India will now be able to reach out to 4,50,000 doctors in India on a consolidated basis, while enhancing the utility and satisfaction levels among doctors by leveraging the strengths of both platforms. It will also enable M3 India to escalate its marketing support and market research businesses to pharmaceutical and medical devices companies through expansion of doctor membership and enhancement of medical education contents”, Amit Singh,CEO, HI (M3 India) said.
“We are very excited with this development. The Indian doctor community is very active on DailyRounds and Marrow. With the support of M3 we will be offering better services to existing doctors. Further we hope to bring in new doctors as well. The goal is to be the largest doctor network in India, not just by registered numbers, but in terms of active users as well.” Dr Deepu Sebin, CEO, Neuroglia Health, commented.
M3 also intends to import services and technologies developed in Japan and/or internationally into India, such as job placement support services and AI applications, with an aim to build next generation healthcare technologies.